Fig. 5

Biofunctions of LFNPs/siTOX complexes in vivo. A Representative organ distribution of Cy5-siRNA complexes at 6 h and 12 h postinjection, and the fluorescence intensity of Cy5-siRNA from ex vivo analysis (n = 3). B Luc gene silencing of FEGCG complexes and LFNPs3-3 complexes at day 0 and day 2, and the quantification of Luc expression, and ex vivo analysis of the Luc activity (n = 3). C–D Treatment schedule and tumor weight after different treatments with saline, FEGCG/siScr, LFNPs3-3/siScr, and LFNPs3-3/siTOX (n = 5). E–F Survival analysis and quantification of metastatic burden with reflected H and E staining (n = 9). *P < 0.05, **P < 0.01, ****P < 0.0001 by an unpaired two-tailed Student’s t-test or one-way analysis of variance (ANOVA) with Turkey’s multiple comparisons